Paul Brasher, MD
Pulmonary Disease · Owensboro, KYNPI 1912341264
Payments from drug & device makers
Across 259 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- GSK$977
- AstraZeneca$527
- Actelion Pharmaceuticals US, Inc.$451
- Insmed, Inc.$332
- Boehringer Ingelheim$313
- plus $2K from 30 others
What the payments were for
- Travel & lodging$77412%
- Food & beverage$4,82974%
- Education$86013%
- Gifts$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $1,778 |
| GSK | 62 | $977 |
| AstraZeneca | 23 | $527 |
| Actelion Pharmaceuticals US, Inc. | 15 | $451 |
| Insmed, Inc. | 22 | $332 |
| Boehringer Ingelheim | 20 | $313 |
| Olympus America Inc. | 3 | $201 |
| Electromed, Inc. | 9 | $188 |
| United Therapeutics Corporation | 8 | $183 |
| Regeneron Healthcare Solutions, Inc. | 8 | $144 |
| Amgen | 7 | $128 |
| Baxter Healthcare | 6 | $117 |
| Sanofi | 6 | $114 |
| Sunovion Pharmaceuticals Inc. | 7 | $111 |
| Mylan Specialty L.p. | 7 | $98 |
| Jazz Pharmaceuticals Inc. | 4 | $96 |
| Livanova USA, Inc. | 1 | $91 |
| Grifols USA, LLC | 6 | $89 |
| Gilead | 5 | $71 |
| Mayne Pharma Commercial LLC | 3 | $68 |
| Harmony Biosciences LLC | 4 | $67 |
| Bayer | 1 | $62 |
| Philips North America LLC | 4 | $61 |
| Merck | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Teleflex LLC | 1 | $20 |
| Pulmonx Corporation | 1 | $18 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,614
- BREZTRI$121
- FASENRA$121
- AIRSUPRA$121
- TEZSPIRE$121
- Spiration Valve System$110
How this compares
$6,564 in reported general payments places this provider in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 710 | $528,057 |
| OfevNintedanib Esylate | 26 | $333,747 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 278 | $150,694 |
| Fasenra PenBenralizumab | 27 | $149,905 |
| OpsumitMacitentan | 11 | $141,764 |
| NucalaMepolizumab | 33 | $119,899 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 150 | $99,764 |
| Dupixent PenDupilumab | 17 | $63,160 |
| Spiriva RespimatTiotropium Bromide | 81 | $56,005 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $38,015 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $32,960 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $15,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 458 | $13,488 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 24 | $9,646 |
| Spiriva HandihalerTiotropium Bromide | 18 | $9,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $977 | $726,894883 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $313 | $540,445385 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $451 | $141,76411 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $527 | $124,980233 claims |
| MerckDulera | $58 | $9,06113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Owensboro
- Michael MuzooraOwensboro$18K
- Rejmon DedajOwensboro$14K
- Berhanemeskel NesketaOwensboro$14K
- Thomas WaringOwensboro$13K
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.